Iterum Therapeutics (ITRM) Q3 2024 earnings summary

Executive summary

• Received FDA approval for Orlynvah (oral sulopenem), the first oral penem-class antibiotic in the U.S. for adult women with uUTI who have limited or no alternative oral antibacterial options, in October 2024.

• Orlynvah addresses a significant unmet need due to rising resistance rates and lack of new oral uUTI treatments in over 25 years.

• Strategic process renewed to seek a partner, acquirer, or other alternatives for Orlynvah post-approval.

• Accumulated deficit reached $479.5 million as of September 30, 2024, with no product revenue generated.

• Substantial doubt exists about ability to continue as a going concern without additional funding.

Financial highlights

• Total operating expenses were $4.9 million in Q3 2024, down from $16.7 million in Q3 2023, mainly due to lower R&D costs after completion of the REASSURE trial.

• Net loss (GAAP) was $6.1 million in Q3 2024 versus $3.9 million in Q3 2023; non-GAAP net loss was $4.8 million, a significant improvement from $15.7 million in Q3 2023.

• Cash, cash equivalents, and short-term investments totaled $14.5 million at September 30, 2024, with additional funds raised post-quarter.

• Net cash used in operating activities was $22.5 million for the nine months ended September 30, 2024, compared to $26.5 million in the prior year period.

• Total assets were $15.9 million and total liabilities $27.4 million as of September 30, 2024, resulting in a shareholders' deficit of $11.5 million.

Outlook and guidance

• Cash runway expected to fund operations into 2025, including repayment of $11.1 million exchangeable notes due January 31, 2025.

• Current cash resources, including recent equity raises, are not sufficient to fund operations for the next 12 months; additional capital is required.

• Strategic alternatives under evaluation include licensing, sale, or divestiture of assets; no assurance of successful transaction or timing.

• If unable to secure funding or strategic transaction, may be forced to delay, scale back, or discontinue development and commercialization activities.